STOCK TITAN

CEL-SCI Corp - CVM STOCK NEWS

Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.

CEL-SCI Corp (CVM) is a clinical-stage biotechnology leader advancing innovative immunotherapies for cancer, infectious diseases, and autoimmune conditions. This page provides investors and researchers with timely updates on the company’s clinical trials, regulatory milestones, and strategic initiatives.

Access authoritative reporting on Multikine Phase 3 head and neck cancer trials, LEAPS platform developments, and collaborative research with institutions like the University of Georgia. Our curated news collection ensures you stay informed about material events influencing CEL-SCI’s scientific and operational trajectory.

Key updates include treatment efficacy data, FDA communications, intellectual property advancements, and partnership announcements. All content is rigorously verified to provide actionable insights for stakeholders monitoring immunotherapy innovations.

Bookmark this page for streamlined access to CEL-SCI’s latest developments. Check regularly for unbiased reporting on breakthroughs that shape the future of immune-based therapies.

Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) announced results from a pivotal 9.5-year Phase 3 study of its immunotherapy Multikine for advanced primary squamous cell carcinoma of the head and neck. The treatment demonstrated a statistically significant 14.1% overall survival benefit (OS) at 5 years (62.7%) for patients not receiving chemotherapy. The study enrolled 928 patients across 78 sites, showing no safety issues. Although the overall trial did not meet the primary endpoint, the results for the chemotherapy-free subgroup warrant an FDA approval request, highlighting an unmet medical need for around 155,000 patients annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.41%
Tags
-
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) is hosting its Annual Shareholder Meeting on July 1, 2021, at 10:00 a.m. EDT. Participants can submit questions until June 29, 2021, at 5:00 p.m. EDT via email. Due to COVID-19 concerns, the meeting will be hybrid, held both in-person and virtually. CEL-SCI is focused on cancer immunotherapy with its lead product, Multikine, in a pivotal Phase 3 trial for head and neck cancer, having received FDA Orphan Drug Status.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
none
-
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) has successfully closed the offering of 1,400,000 shares of its common stock at a price of $22.62 per share, amounting to approximately $31.7 million in gross proceeds. The underwriter, Kingswood Capital Markets, has a 30-day option to purchase an additional 210,000 shares to cover over-allotments. This offering was made under a 'shelf' registration statement with the SEC. CEL-SCI is focused on developing immunotherapy treatments, with its lead therapy, Multikine, in a pivotal Phase 3 trial for head and neck cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) announced an increased public offering of 1,400,000 shares of common stock at $22.62 per share, a 5% discount to the last closing price. The offering, expected to close around June 11, 2021, will fund the development of Multikine and other corporate purposes. Kingswood Capital Markets is the sole book-runner. The offering is registered under an S-3 shelf registration. Investors are reminded that the offering is subject to market conditions and other risks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.5%
Tags
none
-
News
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) announced an underwriting agreement with Kingswood Capital Markets to sell a minimum of 1,000,000 shares at $22.62 per share, a 5% discount from the June 8, 2021 closing price. The offering is set to close around June 11, 2021, subject to customary conditions. A 30-day option is granted to purchase an additional 15%. Proceeds will fund the development of Multikine and other corporate purposes. The shares are offered under a "shelf" registration statement with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.5%
Tags
none
-
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) announced its financial results for Q2 2021, reporting an operating loss of $8.5 million, up from $6.7 million in Q2 2020. For the six months ended March 31, 2021, losses reached $17.3 million, compared to $13.6 million in the prior year. The company is in the statistical analysis phase of its Phase 3 head and neck cancer study of Multikine, with plans for a commercial launch following the completion of its $10.6 million manufacturing facility upgrade.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.08%
Tags
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) reported its financial results for the quarter ending December 31, 2020, highlighting key clinical developments.

Notably, the Phase 3 head and neck cancer study for Multikine is in statistical analysis, following data lock completion. The company also expanded its cGMP facility to double production capacity. Financially, CEL-SCI recorded a net loss of approximately $7.9 million, compared to $5.5 million for the same quarter in 2019. Cash reserves stood at approximately $21.9 million as of December 31, 2020, bolstered by a public offering that raised about $13.6 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
-
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) announced that CEO Geert Kersten will present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference from January 11-14, 2021. The presentation will be available on-demand starting January 11 at 6:00 AM ET. CEL-SCI's Phase 3 study focuses on Multikine, an investigational cancer immunotherapy specifically targeting advanced squamous cell carcinoma of the head and neck. The study aims to boost patients' immune responses before undergoing standard treatments, with 928 patients fully enrolled as of September 2016.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
conferences
-
Rhea-AI Summary

CEL-SCI Corporation (NYSE American: CVM) has issued a letter to shareholders emphasizing its investigational cancer immunotherapy, Multikine. The company aims to improve survival rates for head and neck cancer through early immune system activation before conventional treatments. It is finalizing results from a pivotal Phase 3 study, which has taken nearly a decade to complete. The letter highlights the complexity of the study, including past challenges with a CRO, and reassures stakeholders of ongoing FDA oversight and positive expectations for Multikine's efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.92%
Tags
none
Rhea-AI Summary

CEL-SCI Corporation (CVM) reported its fiscal year 2020 results, highlighting key developments in its Phase 3 study of Multikine for head and neck cancer. The study reached a crucial milestone with 298 events, leading to data analysis. The company raised approximately $25.8 million in 2020 and an additional $14.7 million post-fiscal year. However, CEL-SCI recorded a net loss of $30.3 million, up from $22.1 million in 2019, primarily due to increased R&D and administrative expenses. The company is also advancing LEAPS immunotherapy for COVID-19 and rheumatoid arthritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
CEL-SCI Corp

NYSE:CVM

CVM Rankings

CVM Stock Data

21.66M
82.27M
2.26%
8.78%
6.87%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
VIENNA